226 related articles for article (PubMed ID: 31768316)
1. Microphthalmia family of transcription factors associated renal cell carcinoma.
Xie L; Zhang Y; Wu CL
Asian J Urol; 2019 Oct; 6(4):312-320. PubMed ID: 31768316
[TBL] [Abstract][Full Text] [Related]
2. Translocation Renal Cell Carcinoma: An Update on Clinicopathological and Molecular Features.
Inamura K
Cancers (Basel); 2017 Aug; 9(9):. PubMed ID: 28850056
[TBL] [Abstract][Full Text] [Related]
3. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH.
Xia QY; Wang XT; Ye SB; Wang X; Li R; Shi SS; Fang R; Zhang RS; Ma HH; Lu ZF; Shen Q; Bao W; Zhou XJ; Rao Q
Histopathology; 2018 Apr; 72(5):786-794. PubMed ID: 29148086
[TBL] [Abstract][Full Text] [Related]
4. Translocation carcinomas of the kidney.
Argani P
Genes Chromosomes Cancer; 2022 May; 61(5):219-227. PubMed ID: 34704642
[TBL] [Abstract][Full Text] [Related]
5. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
[TBL] [Abstract][Full Text] [Related]
6. MiT family translocation renal cell carcinoma.
Argani P
Semin Diagn Pathol; 2015 Mar; 32(2):103-13. PubMed ID: 25758327
[TBL] [Abstract][Full Text] [Related]
7. MiT/TFE Family Renal Cell Carcinoma.
Tang J; Baba M
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672892
[TBL] [Abstract][Full Text] [Related]
8. [MiT family translocation renal cell carcinomas: Natural history, molecular features and multidisciplinary management].
Herrscher H; Boilève A; Lindner V; Barthélémy P; Hutt É; Pierard L; Kurtz JE; Rioux-Leclercq N; Lang H; Malouf GG
Bull Cancer; 2020 Feb; 107(2):272-280. PubMed ID: 32044098
[TBL] [Abstract][Full Text] [Related]
9. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.
Wang XM; Zhang Y; Mannan R; Skala SL; Rangaswamy R; Chinnaiyan A; Su F; Cao X; Zelenka-Wang S; McMurry L; Xiao H; Spratt DE; Sangoi AR; Shao L; Betz BL; Brown N; Tickoo SK; McKenney JK; Argani P; Gupta S; Reuter VE; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Mod Pathol; 2021 Aug; 34(8):1596-1607. PubMed ID: 33854184
[TBL] [Abstract][Full Text] [Related]
10. Xp11 Translocation Renal Cell Carcinoma and the Mesenchymal Counterparts: An Evolving Concept with Novel Insights on Clinicopathologic Features, Prognosis, Treatment, and Classification.
Wang XT; Xia QY; Zhou XJ; Rao Q
Crit Rev Oncog; 2017; 22(5-6):481-497. PubMed ID: 29604926
[TBL] [Abstract][Full Text] [Related]
11. Histological and molecular characterization of TFEB-rearranged renal cell carcinomas.
Wyvekens N; Rechsteiner M; Fritz C; Wagner U; Tchinda J; Wenzel C; Kuithan F; Horn LC; Moch H
Virchows Arch; 2019 May; 474(5):625-631. PubMed ID: 30706129
[TBL] [Abstract][Full Text] [Related]
12. Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a micropapillary pattern: cases report and literature review.
Xu ZY; Wang JP; Zhang Y; Wu SW; Ma L; Qin YZ; Wang ZP; Chai DM; Tao YS
Am J Transl Res; 2019; 11(1):327-339. PubMed ID: 30787990
[TBL] [Abstract][Full Text] [Related]
13. High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.
Lang M; Schmidt LS; Wilson KM; Ricketts CJ; Sourbier C; Vocke CD; Wei D; Crooks DR; Yang Y; Gibbs BK; Zhang X; Klumpp-Thomas C; Chen L; Guha R; Ferrer M; McKnight C; Itkin Z; Wangsa D; Wangsa D; James A; Difilippantonio S; Karim B; Morís F; Ried T; Merino MJ; Srinivasan R; Thomas CJ; Linehan WM
J Exp Clin Cancer Res; 2023 Apr; 42(1):99. PubMed ID: 37095531
[TBL] [Abstract][Full Text] [Related]
14. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
15. A review of neoplasms with MITF/MiT family translocations.
Wei S; Testa JR; Argani P
Histol Histopathol; 2022 Apr; 37(4):311-321. PubMed ID: 35107169
[TBL] [Abstract][Full Text] [Related]
16. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
[TBL] [Abstract][Full Text] [Related]
17. The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing.
Cajaiba MM; Dyer LM; Geller JI; Jennings LJ; George D; Kirschmann D; Rohan SM; Cost NG; Khanna G; Mullen EA; Dome JS; Fernandez CV; Perlman EJ
Cancer; 2018 Aug; 124(16):3381-3389. PubMed ID: 29905933
[TBL] [Abstract][Full Text] [Related]
18. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
[TBL] [Abstract][Full Text] [Related]
19. Racial Disparities in MiT Family Translocation Renal Cell Carcinoma.
Lu X; Tawanaie Pour Sedehi N; Su X; Yan F; Alhalabi O; Tannir NM; Malouf GG
Oncologist; 2023 Nov; 28(11):1009-1013. PubMed ID: 37315151
[TBL] [Abstract][Full Text] [Related]
20. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]